However, an HRd phenotype resulting from CDK12 loss has not been confirmed in assessments of patient tumors or clinically with therapeutics that exploit HRd, and there are conflicting reports on the presence of HRd-associated genomic ‘scars’ in CDK12 mutant cancers (9, 30–33). The gene discussed is CDK12; the disease is cancer.